Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.
Also called NCT01918332
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 168 participants
- Sponsor
- Registry
-
NCT01918332
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01918332. Randomized; triple masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2014-12-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
- Condition
- Hypertension,
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Valsartan 160mg
- Intervention (Drug)
- Rosuvastatin 20mg
- Intervention (Drug)
- Valsartan 160mg placebo
- Intervention (Drug)
- Rosuvastatin 20mg placebo
- Lead sponsor
- LG Life Sciences
Record details
- Record id
cardio:ct-nct01918332- Content hash
d2868cc583d64ce8069be3b4af0d5c27a0a3e6b0dae2d64af45ce32b6b184510